Residential Course - Clinical Oncology: Head & Neck Cancers

Scientific Coordinator: L. Licitra, IT


This residential course on head and neck cancers is addressed to an International audience of clinical oncologists interested in advancing their knowledge and skills on the clinical management of these tumors in a multidisciplinary context.
Taking into account that “networking” is the keyword to improve quality of care of rare cancers, the course is developed in the framework of EURACAN , the European Reference Network on rare adult solid cancers, with the aim of reinforcing the collaboration among oncologists of different countries who are already part of the network or willing to be part of it in the near future.
Attendance is limited to 30 participants and the admission will be on competitive application only.

LEARNING OBJECTIVES
To provide an overview of current multidisciplinary state-of-the-art treatment of head and neck cancers
To discuss relevant clinical cases on a multidisciplinary basis
To establish connections for future distance clinical mentoring/tutoring/networking

The residential course on head and neck cancers is an ESO - EURACAN joint initiative
In the framework of
Held in collaboration with

INVITED
S. Alfieri, Fondazione IRCCS Istituto Nazionale Tumori, Milano, IT
P. Bossi, Medical Oncology, University of Brescia, IT
P.G. Casali, Fondazione IRCCS Istituto Nazionale Tumori, Milano, IT
J.G. Eriksen, Aarhus University Hospital, Aarhus, DK
G. Gatta, Fondazione IRCCS Istituto Nazionale Tumori, Milano IT
C . Gavazzi, Fondazione IRCCS Istituto Nazionale Tumori, Milano, IT
V. Gregoire, Universitè Catholique, Louvain, BE
A. Iacovelli, Fondazione IRCCS Istituto Nazionale Tumori, Milano, IT
A.D. Jensen, Dept. Radiation Oncology, Heidelberg Univ. Hospital, Heidelberg, DE
L. Licitra, Fondazione IRCCS Istituto Nazionale Tumori, Milano, IT
L. Locati, Fondazione IRCCS Istituto Nazionale Tumori, Milano, IT
P. Morbini, Department of Pathology, University of Pavia, IT
P. Nicolai,  ASST Spedali Civili,  Brescia, IT
S. Nuyts, University Hospitals, Leuven , BE
E. Orlandi, Fondazione IRCCS Istituto Nazionale Tumori, Milano, IT
C. Piazza, Fondazione IRCCS Istituto Nazionale Tumori, Milano, IT
L. Preda, Istituto Europeo di Oncologia, Milano, IT
A. Schindler, Department of Clinical and Biomedical Sciences, University of Milan, IT
C. Simon, Université de Lausanne, CHUV Lausanne, CH
A. Trama, Fondazione IRCCS Istituto Nazionale Tumori, Milano IT

ORGANISING SECRETARIAT
European School of Oncology
Rare Tumours Programme
Marina Fregonese
email: mfregonese@eso.net
phone: +39 02 23902106

ACCREDITATION
Application for CME recognition will be submitted to the European Accreditation Council for Continuing Medical Education (EACCME) and to the Italian CME accreditation system.
EACCME credits are recognised by the American Medical Association towards the Physician’s Recognition Award (PRA).
Information on the status of the applications can be obtained from the organising Secretariat.

OFFICIAL LANGUAGE
The official language will be English. No translation will be provided.

VENUE
Villa Verganti Veronesi
Viale Lombardia 33
20010 Inveruno
Italia

HOW TO REACH THE VENUE

TRAVEL GRANTS
ESO is pleased to announce that 3 travel grants for the amount of € 500 each will be given to the top 3 candidates from the applications received.

The grant is a contribution to travel and accommodation costs which should be organized by the participants themselves.
The grant will be paid after the course. Attendance is mandatory.

PARTICIPANT'S PROFILE
• Medical degree
• Current involvement in clinical activities in oncology
• Fluency in English

HOW TO APPLY
Priority will be given to younger candidates and low/middle income countries.
Only applications with all required information and attachments will be considered.

ATTENDANCE TO THE COURSE IS BY APPLICATION ONLY FOR A MAXIMUM OF 30 PARTICIPANTS.
Successful applicants are granted free registration. Travel and accommodation will not be covered and must be organized by participants.

1 April

 2 April

 3 April

4 April